CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 98 enrolled
Drug / intervention
HIV therapydrug
Likely dose
HIV therapy 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01275625
NCT01275625Phase 4Completed
CompareCT.gov

A Multicenter, Open Label Study Of Maraviroc, Zidovudine And Lamivudine Twice Daily For The Treatment Of Antiretroviral Naïve HIV-Infected Patients With R5 HIV-1 In Russia

ViiV Healthcare·interventional·Posted Jan 12, 2011·Updated Mar 3, 2014

In Brief

A Phase 4 clinical trial evaluating HIV therapy for HIV. Completed, enrolled 98 participants across 8 sites.

Detailed Summary

One hundred subjects in Russia will be treated with a combination of Combivir (zidovudine and lamivudine) and maraviroc as their first line HIV therapy. The aim is to assess the efficacy and safety of this combination in a Russian population of patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV
CountriesRussia
CollaboratorsPfizer

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 12, 2011
Enrollment StartJun 1, 2011
Primary CompletionOct 1, 2012
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.5 years ago

Interventions

HIV therapydrug

Combivir one tablet BD with maraviroc 300mg BD for 48 weeks